Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)

CAPS Rating: 3 out of 5

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.


Player Avatar justaboutperfect (< 20) Submitted: 5/29/2012 10:49:37 AM : Underperform Start Price: $53.90 VRTX Score: +1.81

When a Biotech misleads and overstates results from tests to investors, its game over and management should resign and give all their stock options back. What a bunch of losers. Shorts got this one right again. I am glad I was not an institutional investor in this company.

Featured Broker Partners